DaVita Inc. (NYSE:DVA) Shares Bought by Harvest Fund Management Co. Ltd

Harvest Fund Management Co. Ltd lifted its holdings in DaVita Inc. (NYSE:DVA) by 14.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,142 shares of the company’s stock after purchasing an additional 1,399 shares during the period. Harvest Fund Management Co. Ltd’s holdings in DaVita were worth $1,826,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently bought and sold shares of the company. Harvard Management Co. Inc. purchased a new stake in shares of DaVita in the second quarter valued at approximately $55,115,000. Point72 Asset Management L.P. purchased a new stake in DaVita in the 2nd quarter worth $9,615,000. KBC Group NV raised its position in DaVita by 27.3% during the third quarter. KBC Group NV now owns 313,519 shares of the company’s stock worth $51,395,000 after acquiring an additional 67,250 shares during the period. International Assets Investment Management LLC purchased a new position in DaVita in the 3rd quarter valued at about $10,346,000. Finally, Hennessy Advisors Inc. purchased a new stake in shares of DaVita during the second quarter worth approximately $8,439,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Stock Up 0.9 %

Shares of NYSE DVA opened at $166.99 on Tuesday. The company has a market capitalization of $13.69 billion, a P/E ratio of 18.01, a P/E/G ratio of 0.93 and a beta of 0.89. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33. The company has a 50 day simple moving average of $158.34 and a 200-day simple moving average of $148.65. DaVita Inc. has a 1 year low of $98.26 and a 1 year high of $169.12.

DaVita (NYSE:DVA) last posted its earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.76 by ($0.17). The business had revenue of $3.26 billion for the quarter, compared to analyst estimates of $3.25 billion. DaVita had a return on equity of 88.18% and a net margin of 6.53%. DaVita’s revenue was up 4.6% compared to the same quarter last year. During the same period last year, the business earned $2.85 EPS. On average, equities research analysts predict that DaVita Inc. will post 9.71 earnings per share for the current year.

Insider Transactions at DaVita

In related news, CEO Javier Rodriguez sold 50,000 shares of the firm’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the completion of the transaction, the chief executive officer now directly owns 837,835 shares in the company, valued at $138,284,666.75. This trade represents a 5.63 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 2.00% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on DVA. Barclays increased their target price on shares of DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. Bank of America raised their target price on shares of DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research note on Wednesday, August 7th. Truist Financial upped their price target on DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research report on Monday, October 7th. Finally, UBS Group lifted their price objective on DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $161.80.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.